In a recent study published in JAMA Neurology a group of researchers determined the utility of a novel and commercially available immunoassay for plasma phosphorylated tau 217 (p-tau217) to detect Alzheimer’s Disease (AD) pathology and evaluate reference ranges for abnormal amyloid β (Aβ) and longitudinal change across three selected cohorts.
Blood biomarkers have become key in AD diagnosis, offering a more scalable option than cerebrospinal fluid (CSF) or positron emission tomography (PET) scans. They are particularly beneficial in settings with limited access to advanced testing, paving the way for early and precise diagnosis and better patient management. p-tau, especially p-tau at threonine 217 (p-tau217), stands out as a leading blood biomarker. It excels in differentiating AD from other conditions and detecting AD in mild cognitive impairment cases, often outperforming other tau biomarkers.
As the medical community moves towards anti-Aβ therapies for dementia, validated blood biomarkers like p-tau217 are crucial for guiding treatment. Further research is necessary to validate plasma p-tau217 across diverse memory clinic populations, addressing comorbidities to enhance its clinical utility for AD.
Comments are closed.